[1] Haensler J, Even L, Wils P, et al. Not so cold! Improving the thermostability of mRNA vaccines. Expert Review of Vaccines. 2025;24(1):1149-1162. DOI: 10.1080/14760584.2025.2596674.

[2] Packer M, Gyawali D, Yerabolu R, Schariter J, White P. A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems. Nature Communications. 2021;12:6777. DOI: 10.1038/s41467-021-26926-0.

[3] Hashiba K, Taguchi M, Sakamoto S, et al. Overcoming thermostability challenges in mRNA-lipid nanoparticle systems with piperidine-based ionizable lipids. Communications Biology. 2024;7:556. DOI: 10.1038/s42003-024-06235-0.

[4] Kafle U, Truong HQ, Nguyen CTG, et al. Development of thermally stable mRNA-LNP delivery systems: current progress and future prospects. Molecular Pharmaceutics. 2024;21(12):5944-5959. 

DOI: 10.1021/acs.molpharmaceut.4c00826.

[5] Pogocki D, Schöneich C. Chemical stability of nucleic acid-derived drugs. Journal of Pharmaceutical Sciences. 2000;89(4):443-456.

[6] Li Y, Breaker RR. Kinetics of RNA degradation by specific base catalysis of transesterification involving the 2′-hydroxyl group. Journal of the American Chemical Society. 1999;121:5364-5372.

[7] Oivanen M, Kuusela S, Lönnberg H. Kinetics and mechanisms for the cleavage and isomerization of the phosphodiester bonds of RNA by Brønsted acids and bases. Chemical Reviews. 1998;98:961-990.

[8] Burrows CJ, Muller JG. Oxidative nucleobase modifications leading to strand scission. Chemical Reviews. 1998;98:1109-1152.

[9] Hald Albertsen C, Kulkarni JA, Witzigmann D, et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Advanced Drug Delivery Reviews. 2022;188:114416.

[10] Brader ML, Williams SJ, Banks JM, et al. Encapsulation state of messenger RNA inside lipid nanoparticles. Biophysical Journal. 2021;120(14):2766-2770.

[11] Kamiya M, Matsumoto M, Yamashita K, et al. Stability study of mRNA-lipid nanoparticles exposed to various conditions based on physicochemical properties and protein expression ability. Pharmaceutics. 2022;14(11):2357.

[12] Tong X, Raffaele J, Feller K, et al. Correlating stability-indicating biochemical and biophysical characteristics with in vitro cell potency in mRNA LNP vaccine. Vaccines. 2024;12(2):169.

[13] Kim B, Hosseinidoust Z, et al. Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines. Molecular Therapy Methods & Clinical Development. 2022.

[14] Reinhart A-G, Osterwald A, Ringler P, et al. Investigations into mRNA lipid nanoparticles shelf-life stability under nonfrozen conditions. Molecular Pharmaceutics. 2023;20(12):6492-6503. DOI: 10.1021/acs.molpharmaceut.3c00956.

[15] Shkodra B, et al. Boosting LNP performance: higher concentrations of lipid mixtures improve in vivo gene expression and storage stability. Pharmaceutics. 2026;18(1):50. Based on the uploaded Chinese review draft of this study.

[16] Peronin S, Malburet C, Daher-Hassan C, et al. Analytical approach for identification and mechanistic insights into mRNA-lipid adduct formation. Molecular Therapy Nucleic Acids. 2025;36(3):102684.

[17] Fang Y, et al. Reversible RNA 2′-OH acylation for RNA stabilization and functional recovery. discussed in Haensler et al. 2025 review

[18] Zuidam NJ, Gouw HK, Barenholz Y, et al. Physical instability of liposomes upon chemical hydrolysis: the role of lysophospholipids and fatty acids. Biochimica et Biophysica Acta. 1995;1240:101-110.

[19] Kumru OS, Joshi SB, Smith DE, et al. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. Biologicals. 2014;42(5):237-259.

[20] Crommelin DJA, Anchordoquy TJ, Volkin DB, et al. Addressing the cold reality of mRNA vaccine stability. Journal of Pharmaceutical Sciences. 2021;110(3):997-1001.